Bayer’s Kerendia, already FDA approved in one cardiometabolic indication, now has data from a pivotal test that support expanding the drug’s label to heart failure. In preliminary results reported ...

The 22-year-old FDA warning advised doctors that hormone therapy increases the risk of blood clots, heart problems, and other ...

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly ...

With one heart failure nod already in the books, Eli Lilly and Boehringer Ingelheim’s diabetes blockbuster Jardiance just racked up another key approval—opening the door to a much wider range of ...

Amarin has rolled out new Vascepa data that could change the way doctors prevent heart disease. Monday, the company trumpeted more data showing its fish oil-derived Vascepa could significantly cut ...

Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first obesity ...

Please provide your email address to receive an email when new articles are posted on . More than one-third of patients without ACS who underwent PCI were prescribed prasugrel or ticagrelor between ...